A new research conducted by 50 centers around the world finds that new injectable antiretroviral therapy (ART) could be as effective as the standard oral treatment. According to reports, the researchers involved in the new study found that antiretroviral therapy that is intramuscularly administered could be as effective as the current standard oral therapy.
As already mentioned above, the new study is a Phase II clinical trial conducted by 50 medical centers – 9 in Spain – across the globe. It is reported by Science Daily that the researchers involved in the study stated that the findings will further boost the implantation of all-injectable antiretroviral therapies. The report stated that the therapy records a low administration frequency, but the new findings could lead to an improved quality of life for HIV patients.
The study involved 286 patients who have previously suppressed viral loads. While conducting the study, the researchers checked the effectiveness of the combination of rilpivirine – a no nucleoside -injected intramuscularly every 4 or 8 weeks and carbotegravir – a new inegrase inhibitor. This was in comparison to the standard ART therapy of three orally-administered drugs: abacavir – lamivudine and carbotegravir.
“This is the first time that all-injectable ART has been used in a trial; In addition, it consists of only 2 drugs, something that is not new but that supports the paradigm shift of 3 to 2 drugs in some virologically suppressed patients,” Chief of the HIV and STD Unit of the Infectious Diseases Service of Bellvitge University hospital (HUB) and the principal investigator of the Bellvitge Biomedical Research Institute (IDIBELL), Dr. Daniel Podzamczer said.
It is reported by Eurekalert that the researchers found after 96 weeks, that up to 87 percent of the study participants treated every 4 weeks and up to 94 percent of those treated every 8 weeks maintained viral load suppression. The study authors stated that the findings show that the injectable antiretroviral therapy is more effective compared to the standard oral treatment, in which participants recorded 84 percent viral load suppression.
Furthermore, the researchers evaluated the level of satisfaction among study participants and found that up to 90 percent of patients in the group treated with injectable antiretroviral therapy reported that they were very satisfied when asked if they will like to continue with the therapy. The findings of the study were published in the journal The Lancet.